Back to search

Article

4-Phenylbutyrate for STXBP1 and SLC6A1. Safety, tolerability, seizure, and EEG outcomes. A case series at 2 centers

2024-11-08

Abstract excerpt

<h4>ABSTRACT</h4> <h4>Introduction</h4> Pathogenic mutations in STXBP1 and SLC6A1 can cause developmental delay and epilepsy. 4-phenylbutyrate (4PB), a drug used for urea cycle disorders, rescues dysfunction in pre-clinical models for both genes, suggesting an opportunity for drug repurposing. <h4>Methods</h4> We conducted a single-treatment group, multiple-dose, open-label study of 4PB (as glycerol phenylbutyr...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
36f932c7-3731-5a04-bace-cf8ff021cd6e
DOI
10.1101/2024.11.06.24316676
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
4-Phenylbutyrate for STXBP1 and SLC6A1. Safety, tolerability, seizure, and EEG outcomes. A case series at 2 centersDOI 10.1101/2024.11.06.24316676
Select a neighboring publication to make it the new centre.